June 15, 2026 · Phase 2 readout
ZBIO Phase 2 readout: a negative outcome, -5.5%
On June 15, 2026, Obexelimab — Zenas BioPharma, Inc. (IgG4 Related Disease) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -5.5% in the window around the event. It had already run +8.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$19.80
1d before
$18.71
Event day
$18.19
1d after
$19.78
5d after
Our prediction vs. the result
CatalystAlert called this one up (+6.3% expected); the stock actually moved -5.5%. Model confidence at the time: 60%.
See the full scored track recordPre-catalyst setup
+8.0%
30-day run-up
7509%
30-day volatility
2.3×
volume spike